204 related articles for article (PubMed ID: 9830626)
1. The oral fluorouracil prodrugs.
Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
[TBL] [Abstract][Full Text] [Related]
2. Oral therapy for colorectal cancer: how to choose.
Damjanov N; Meropol NJ
Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
[TBL] [Abstract][Full Text] [Related]
3. Oral fluoropyrimidines in colorectal cancer.
Van Cutsem E; Peeters M
Semin Oncol; 2000 Oct; 27(5 Suppl 10):91-5. PubMed ID: 11049039
[No Abstract] [Full Text] [Related]
4. Oral fluoropyrimidines: a closer look at their toxicities.
Macdonald JS
Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
[TBL] [Abstract][Full Text] [Related]
5. Oral fluoropyrimidine treatment of colorectal cancer.
Eng C; Kindler HL; Schilsky RL
Clin Colorectal Cancer; 2001 Aug; 1(2):95-103. PubMed ID: 12445367
[TBL] [Abstract][Full Text] [Related]
6. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
7. Colorectal cancer: chemotherapy treatment overview.
Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
[TBL] [Abstract][Full Text] [Related]
8. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience.
Lima AP; del Giglio A
Eur J Cancer Care (Engl); 2005 May; 14(2):151-4. PubMed ID: 15842464
[TBL] [Abstract][Full Text] [Related]
9. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
[TBL] [Abstract][Full Text] [Related]
10. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
12. [Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Hosokawa A
Nihon Rinsho; 2003 Sep; 61 Suppl 7():352-5. PubMed ID: 14574911
[No Abstract] [Full Text] [Related]
13. Answering patients' needs: oral alternatives to intravenous therapy.
Borner M; Scheithauer W; Twelves C; Maroun J; Wilke H
Oncologist; 2001; 6 Suppl 4():12-6. PubMed ID: 11585969
[TBL] [Abstract][Full Text] [Related]
14. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Hoff PM
Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
16. Fluoropyrimidines: a critical evaluation.
Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
[TBL] [Abstract][Full Text] [Related]
17. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
19. UFT/leucovorin vs 5-FU/leucovorin in colon cancer.
Smith RE; Lembersky BC; Wieand HS; Colangelo L; Mamounas EP
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):24-7. PubMed ID: 11098486
[TBL] [Abstract][Full Text] [Related]
20. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
